

Name : Mrs. AISHA SIDDIQUI

Age: 51 Y

Sex: F

Address: DELHI

: ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN

INDIA OP AGREEMENT

UHID:SCHI.0000017917

OP Number: SCHIOPV25856

**Bill No :**SCHI-OCR-9337 **Date :** 09.02.2024 10:31

Sno	Serive Type/ServiceName	Department
1	ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY23:	24
	GAMMA GLUTAMYL TRANFERASE (GGT)	
	LIVER FUNCTION TEST (LFT)	
	GLUCOSE, FASTING	
4	HEMOGRAM + PERIPHERAL SMEAR	
	GYNAECOLOGY CONSULTATION	
(	DIET CONSULTATION Defler reporte	
	COMPLETE URINE EXAMINATION	
	PERIPHERAL SMEAR	
9	ECG NIAWN	
(10	DBC PAP TEST- PAPSURE * Petried	
1	RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
(12	DENTAL CONSULTATION A	
1.	Hbaic, GLYCATED HEMOGLOBIN	
(14	ENT CONSULTATION DR. LM PART SHAR	
1:	FITNESS BY GENERAL PHYSICIAN	
10	BLOOD GROUP ABO AND RH FACTOR	
1	7 LIPID PROFILE -	
18	BODY MASS INDEX (BMI)	
	OPTHAL BY GENERAL PHYSICIAN	
(20	ULTRASOUND - WHOLE ABDOMEN •	
2	THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	

TSH 8-29

Height: 80.2 to Man has B.P: 80 mt has Pulse: 80 mt

Booking ID	EMP-NAME	AGE	GENDER
UBOIES3456	ABID KARIM	51 year	Male
UBOIES3456	aisha	50 year	Female





# भारत सरकार

Unique Identification Authority of India Government of India

नामांकन क्रम / Enrollment No 1047/10102/07944

आएशा सिद्दिकी Aisha Siddiqui W/O Abid Karim 41-S SECTOR-8 JASOLA VIHAR New Friends Colony S.O New Friends Colony South Delhi Delhi 110025

Ref: 113 / 09B / 208684 / 209108 / P



UE033561309IN



आपका आधार क्रमांक / Your Aadhaar No. :

6876 1675 5191

आघार — आम आदमी का अधिकार



भारत सरकार GOVERNMENT OF INDIA



आएशा सिद्दिकी Aisha Siddiqui जन्म वर्ष / Year of Birth: 1973 महिला / Female



6876 1675 5191

आघार — आम आदमी का अधिकार



NAME:	AISHA SIDDIQUI	AGE/SEX	51	YRS/ F
UHID:	17917	<u> </u>		
REF BY:	APOLLO SPECTRA	DATE:-	09.02	2.2024

#### **ULTRASOUND WHOLE ABDOMEN**

Liver: Appears normal in size and shows increased parenchymal echogenicity which is most likely due to fatty changes. Intrahepatic biliary radicles are not dilated. CBD and portal vein are normal in calibre.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

**Both Kidneys**: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

**Urinary Bladder:** is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

**Uterus** is antiverted and normal in size. It measures 6.8 x 2.7 cm. Outline is smooth. Myometrium is normal. Endometrial echoes are normal and measures 5 mm

Both ovaries are normal in size, shape and echotexture. 21mm follicle seen in right ovary.

Right ovary: 2.7 x 2 cm Left ovary: 2.5 x 1.6 cm

No obvious adenexal mass is seen. No free fluid seen.

Umbilical hernia with a defect of 25.8mm is seen.


IMPRESSION: FATTY CHANGES IN LIVER GRADE II

Please correlate clinically and with lab. Investigations.

DR. MONICA CHHABRA CONSULTANT RADIOLOGIST

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

**Apollo Spectra Hospitals:** Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com



# Dr. Lalit Mohan Parashar

MS (ENT) Ear, Nose, Throat Specialist and Head & Neck Surgeon MCI: 4774/85

For Appointmnt: +91 1140465555 Mob.: +91 9910995018 ABNA SIDDIQUI



515

ENT CURICE UP

No LEADING COMP CATINTS

OLE

MSi - SOFTUM MIDLINE

TIMENT NAD

EARS- BL INCO

91=> ENT NORMM

9/2/2024

**Apollo Spectra Hospitals:** Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

# **Apollo Specialty Hospital Pvt. Ltd.**





# **Apollo Clinic**

# **CONSENT FORM**

Patient Name: Aight Age: 57  UHID Number: SCHT. (1900) 17917 Company Name: Ar Cofemi
I Mr/Mrs/Ms Aillu Employee of Arcofemi (Company) Want to inform you that I am not interested in getting PAP Test Tests done which is a part of my routine health check package.  And I claim the above statement in my full consciousness.
Patient Signature: Date: Date:









Age/Gender : 51 Y 0 M 7 D/F

UHID/MR No : SCHI.0000017917 Visit ID : SCHIOPV25856

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : SDETGYZSDRHY

Collected : 09/Feb/2024 10:51AM

Received : 09/Feb/2024 11:13AM Reported : 09/Feb/2024 02:39PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

# **DEPARTMENT OF HAEMATOLOGY**

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

---

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240032182





Ref Doctor



Patient Name : Mrs.AISHA SIDDIQUI

Age/Gender : 51 Y 0 M 7 D/F

UHID/MR No : SCHI.0000017917

Visit ID : SCHIOPV25856

Emp/Auth/TPA ID : SDETGYZSDRHY

: Dr.SELF

Collected : 09/Feb/2024 10:51AM

Received : 09/Feb/2024 11:13AM Reported : 09/Feb/2024 02:39PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

# **DEPARTMENT OF HAEMATOLOGY**

# ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	12.7	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	39.00	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	4.46	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	87.4	fL	83-101	Calculated
MCH	28.4	pg	27-32	Calculated
MCHC	32.5	g/dL	31.5-34.5	Calculated
R.D.W	13.8	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	6,280	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUN	IT (DLC)			
NEUTROPHILS	66.6	%	40-80	Electrical Impedance
LYMPHOCYTES	23.5	%	20-40	Electrical Impedance
EOSINOPHILS	1.7	%	1-6	Electrical Impedance
MONOCYTES	7.7	%	2-10	Electrical Impedance
BASOPHILS	0.5	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	4182.48	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1475.8	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	106.76	Cells/cu.mm	20-500	Calculated
MONOCYTES	483.56	Cells/cu.mm	200-1000	Calculated
BASOPHILS	31.4	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	176000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	08	mm at the end of 1 hour	0-20	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN

Page 2 of 12

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240032182





Age/Gender : 51 Y 0 M 7 D/F
UHID/MR No : SCHI.0000017917

Visit ID : SCHIOPV25856

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : SDETGYZSDRHY

Collected : 09/Feb/2024 10:51AM

Received : 09/Feb/2024 11:13AM Reported : 09/Feb/2024 02:39PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

# **DEPARTMENT OF HAEMATOLOGY**

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240032182



Page 3 of 12





Age/Gender : 51 Y 0 M 7 D/F
UHID/MR No : SCHI.0000017917

Visit ID : SCHIOPV25856

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : SDETGYZSDRHY

Collected : 09/Feb/2024 10:51AM Received : 09/Feb/2024 11:13AM

Reported : 09/Feb/2024 01:24PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

# **DEPARTMENT OF HAEMATOLOGY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA							
BLOOD GROUP TYPE	А			Forward & Reverse Grouping with Slide/Tube Aggluti			
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination			

Page 4 of 12









Age/Gender : 51 Y 0 M 7 D/F

UHID/MR No : SCHI.0000017917

Visit ID : SCHIOPV25856

Ref Doctor : Dr.SELF
Emp/Auth/TPA ID : SDETGYZSDRHY

Collected : 09/Feb/2024 10:51AM

Received : 09/Feb/2024 11:13AM Reported : 09/Feb/2024 01:21PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

# **DEPARTMENT OF BIOCHEMISTRY**

# ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	100	mg/dL	70-100	GOD - POD

#### **Comment:**

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

#### Note

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 5 of 12





Ref Doctor



Patient Name : Mrs.AISHA SIDDIQUI

Age/Gender : 51 Y 0 M 7 D/F

UHID/MR No : SCHI.0000017917

: Dr.SELF

Visit ID : SCHIOPV25856

Emp/Auth/TPA ID : SDETGYZSDRHY Collected : 09/Feb/2024 10:51AM

Received : 09/Feb/2024 12:13PM Reported : 09/Feb/2024 12:56PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

# DEPARTMENT OF BIOCHEMISTRY

#### ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN), WHOLE BLOOD EDTA				
HBA1C, GLYCATED HEMOGLOBIN	5.2	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	103	mg/dL		Calculated

#### **Comment:**

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

**Note:** Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

- B: Homozygous Hemoglobinopathy.
- (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Dr Nidhi Sachdev M.B.B.S, MD(Pathology) Consultant Pathologist

Dr. Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:EDT240014073

Page 6 of 12





Age/Gender : 51 Y 0 M 7 D/F

UHID/MR No : SCHI.0000017917 Visit ID : SCHIOPV25856

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : SDETGYZSDRHY

Collected : 09/Feb/2024 10:51AM

Received : 09/Feb/2024 11:13AM Reported : 09/Feb/2024 01:20PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF BIOCHEMISTRY

#### ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
LIPID PROFILE , SERUM						
TOTAL CHOLESTEROL	188	mg/dL	<200	CHE/CHO/POD		
TRIGLYCERIDES	73	mg/dL	<150	Enzymatic		
HDL CHOLESTEROL	74	mg/dL	>40	CHE/CHO/POD		
NON-HDL CHOLESTEROL	114	mg/dL	<130	Calculated		
LDL CHOLESTEROL	99.4	mg/dL	<100	Calculated		
VLDL CHOLESTEROL	14.6	mg/dL	<30	Calculated		
CHOL / HDL RATIO	2.54		0-4.97	Calculated		

#### **Comment:**

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

Reference interval as per reactional enotesteror Education Program (1962) Padate Production Patient II Report.					
	Desirable	Borderline High	High	Very High	
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240		
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500	
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190	
HDL	≥ 60				
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220	

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 7 of 12



Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:SE04623738





Age/Gender : 51 Y 0 M 7 D/F UHID/MR No : SCHI.0000017917

Visit ID : SCHIOPV25856

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : SDETGYZSDRHY

Collected : 09/Feb/2024 10:51AM

Received : 09/Feb/2024 11:13AM Reported : 09/Feb/2024 01:20PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
LIVER FUNCTION TEST (LFT) , SERUM							
BILIRUBIN, TOTAL	0.50	mg/dL	0.20-1.20	DIAZO METHOD			
BILIRUBIN CONJUGATED (DIRECT)	0.20	mg/dL	0.0-0.3	Calculated			
BILIRUBIN (INDIRECT)	0.30	mg/dL	0.0-1.1	Dual Wavelength			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	42	U/L	<35	Visible with P-5-P			
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	36.0	U/L	14-36	UV with P-5-P			
ALKALINE PHOSPHATASE	117.00	U/L	38-126	p-nitrophenyl phosphate			
PROTEIN, TOTAL	7.80	g/dL	6.3-8.2	Biuret			
ALBUMIN	4.50	g/dL	3.5 - 5	Bromocresol Green			
GLOBULIN	3.30	g/dL	2.0-3.5	Calculated			
A/G RATIO	1.36		0.9-2.0	Calculated			

#### **Comment:**

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

#### 1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI .• Disproportionate increase in AST, ALT compared with ALP. Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

#### 2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 8 of 12



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:SE04623738





Age/Gender : 51 Y 0 M 7 D/F
UHID/MR No : SCHI.0000017917

Visit ID : SCHIOPV25856

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : SDETGYZSDRHY

Collected : 09/Feb/2024 10:51AM

Received : 09/Feb/2024 11:13AM Reported : 09/Feb/2024 01:20PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

# **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM							
CREATININE	0.60	mg/dL	0.5-1.04	Creatinine amidohydrolase			
UREA	20.50	mg/dL	15-36	Urease			
BLOOD UREA NITROGEN	9.6	mg/dL	8.0 - 23.0	Calculated			
URIC ACID	6.00	mg/dL	2.5-6.2	Uricase			
CALCIUM	9.80	mg/dL	8.4 - 10.2	Arsenazo-III			
PHOSPHORUS, INORGANIC	4.30	mg/dL	2.5-4.5	PMA Phenol			
SODIUM	138	mmol/L	135-145	Direct ISE			
POTASSIUM	4.2	mmol/L	3.5-5.1	Direct ISE			
CHLORIDE	102	mmol/L	98 - 107	Direct ISE			

Page 9 of 12







Age/Gender : 51 Y 0 M 7 D/F
UHID/MR No : SCHI.0000017917

Visit ID : SCHIOPV25856

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : SDETGYZSDRHY

Collected : 09/Feb/2024 10:51AM

Received : 09/Feb/2024 11:13AM Reported : 09/Feb/2024 11:57AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

# **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	19.00	U/L	12-43	Glyclyclycine Nitoranalide

Page 10 of 12









Age/Gender : 51 Y 0 M 7 D/F
UHID/MR No : SCHI.0000017917

Visit ID : SCHIOPV25856

Ref Doctor : Dr.SELF
Emp/Auth/TPA ID : SDETGYZSDRHY

Collected : 09/Feb/2024 10:51AM Received : 09/Feb/2024 11:13AM

Received : 09/Feb/2024 11:13AM Reported : 09/Feb/2024 01:20PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF IMMUNOLOGY

#### ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
THYROID PROFILE TOTAL (T3, T4, TSH), SERUM							
TRI-IODOTHYRONINE (T3, TOTAL)	1.28	ng/mL	0.67-1.81	ELFA			
THYROXINE (T4, TOTAL)	8.00	μg/dL	4.66-9.32	ELFA			
THYROID STIMULATING HORMONE (TSH)	8.290	μIU/mL	0.25-5.0	ELFA			

#### **Comment:**

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)		
First trimester	0.1 - 2.5		
Second trimester	0.2 - 3.0		
Third trimester	0.3 - 3.0		

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 12



Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:SPL24021131





Age/Gender : 51 Y 0 M 7 D/F UHID/MR No : SCHI.0000017917

Visit ID : SCHIOPV25856

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SDETGYZSDRHY Collected : 09/Feb/2024 10:51AM Received : 09/Feb/2024 02:27PM

Reported : 09/Feb/2024 07:21PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

# **DEPARTMENT OF CLINICAL PATHOLOGY**

Status

#### ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method	
COMPLETE URINE EXAMINATION (	CUE) , URINE				
PHYSICAL EXAMINATION					
COLOUR	PALE YELLOW		PALE YELLOW	Visual	
TRANSPARENCY	CLEAR		CLEAR	Visual	
pH	6.0		5-7.5	Bromothymol Blue	
SP. GRAVITY	1.030		1.002-1.030	Dipstick	
BIOCHEMICAL EXAMINATION					
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR	
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD	
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING	
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE	
UROBILINOGEN	NORMAL		NORMAL	EHRLICH	
BLOOD	NEGATIVE		NEGATIVE	Dipstick	
NITRITE	NEGATIVE		NEGATIVE	Dipstick	
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS	
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	<b>'</b>			
PUS CELLS	0-2	/hpf	0-5	Microscopy	
EPITHELIAL CELLS	0-2	/hpf	<10	MICROSCOPY	
RBC	ABSENT	/hpf	0-2	MICROSCOPY	
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY	
CRYSTALS	ABSNET		ABSENT	MICROSCOPY	

\*\*\* End Of Report \*\*\*

Page 12 of 12



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:UR2278417